Sign Out
Cardiac Dysfunction, Infusion Reactions, Pulmonary Toxicity And Embryofoetal Toxicity: For complete details, refer to Precautions.
Cardiac Dysfunction: Sub-clinical and clinical cardiac failure may result from treatment with trastuzumab. It may manifest as congestive heart failure and decreased left ventricular ejection fraction. Such events had the highest incidence when trastuzumab was given with chemotherapy regimens containing anthracyclines.
Before and during treatment with trastuzumab, left ventricular function must be evaluated in all patients [refer to Precautions and Dosage & Administration].
Infusion Reactions; Pulmonary Toxicity: Trastuzumab needs to be discontinued for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome [refer to Precautions].
Embryo-Foetal Toxicity: Trastuzumab exposure during pregnancy can result in oligohydramnios and can be complicated by pulmonary hypoplasia and neonatal death [refer to Precautions].
Continue with Google